Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A systems-approach to NAD+ restoration.
Conlon N, Ford D. Conlon N, et al. Biochem Pharmacol. 2022 Apr;198:114946. doi: 10.1016/j.bcp.2022.114946. Epub 2022 Feb 5. Biochem Pharmacol. 2022. PMID: 35134387 Free article. Review.
The Role of NAD+ in Regenerative Medicine.
Conlon NJ. Conlon NJ. Plast Reconstr Surg. 2022 Oct 1;150(4 Suppl ):41S-48S. doi: 10.1097/PRS.0000000000009673. Epub 2021 Sep 28. Plast Reconstr Surg. 2022. PMID: 36170435 Free PMC article.
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis.
Scott J, White A, Walsh C, Aslett L, Rutherford MA, Ng J, Judge C, Sebastian K, O'Brien S, Kelleher J, Power J, Conlon N, Moran SM, Luqmani RA, Merkel PA, Tesar V, Hruskova Z, Little MA. Scott J, et al. Among authors: conlon n. RMD Open. 2024 Apr 30;10(2):e003962. doi: 10.1136/rmdopen-2023-003962. RMD Open. 2024. PMID: 38688690 Free article.
Author Correction: Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment.
Greene C, Connolly R, Brennan D, Laffan A, O'Keeffe E, Zaporojan L, O'Callaghan J, Thomson B, Connolly E, Argue R, Meaney JFM, Martin-Loeches I, Long A, Cheallaigh CN, Conlon N, Doherty CP, Campbell M. Greene C, et al. Among authors: conlon n. Nat Neurosci. 2024 Apr 16. doi: 10.1038/s41593-024-01644-0. Online ahead of print. Nat Neurosci. 2024. PMID: 38627595 No abstract available.
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.
Dungan L, Dunne J, Savio M, Kalaszi M, McElheron M, Lynagh Y, O'Driscoll K, Roche C, Qureshi A, Crowley B, Conlon N, Kearney H. Dungan L, et al. Among authors: conlon n. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200217. doi: 10.1212/NXI.0000000000200217. Epub 2024 Mar 28. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38547427 Free PMC article.
171 results